GlassScriptPhysician profile
Ryan M Maceyko
NPI 1316435613
$9,813.41
in general payments reported to CMS, 2019-2025
17 companies · $2,749 in 2025
The $2,749 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $602 · 2021: $423 · 2022: $1,886 · 2023: $1,584 · 2024: $2,052 · 2025: $2,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,229 · Travel and Lodging: $2,131 · Entertainment: $24.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,229.35 |
| Travel and Lodging | $2,131.04 |
| Entertainment | $24.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,216.55 | 2019-2025 | Precision 1, Total30, Precision7 |
| Johnson & Johnson Vision Care, INC. | $1,969.87 | 2019-2025 | Acuvue |
| Coopervision INC. | $1,930.61 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Biofinity Contact Lens |
| Bausch & Lomb Americas INC. | $1,343.49 | 2022-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $254.67 | 2019-2020 | |
| Biotissue Holdings INC. | $246.23 | 2023 | |
| Abbvie INC. | $122.55 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $121.57 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $119.73 | 2022-2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $97.28 | 2021 | |
| Lombart Brothers, INC. | $89.43 | 2021 | |
| Dompe US, INC. | $86.80 | 2023 | Oxervate |
| Optos, INC. | $67.30 | 2020-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Abb Con-Cise Optical Group LLC | $55.60 | 2020 | |
| Visioneering Technologies, INC. | $43.29 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.79 | 2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $19.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Maceyko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.